How protected are your drug formulations in your transactions?
07 May 2021
An understanding of the value and importance of protecting the formulations during the deal can also be business critical for both parties. There are a number of considerations to assess before agreeing on how to share or transfer the formulation. For example, should the formulation be assigned or licensed; do the product files and dossiers have the right information to ensure the buyer can continue to produce the product; and are the transaction documents complete and appropriately structured? All of these issues and more should be considered during the life cycle of your transaction to ensure both parties realise their strategic objectives.
On 25 May, A&O will be hosting a 45 minute webinar to discuss this further, providing practical tips to ensure drug formulations are protected during your transactions. Registration is essential. Please RSVP here.